desipramine has been researched along with Carcinoma, Hepatocellular in 1 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, anti-proliferative effects of desipramine, a tricyclic antidepressant, in hepatocellular carcinoma are currently unknown." | 7.85 | Desipramine induces apoptosis in hepatocellular carcinoma cells. ( Kim, SJ; Yang, DK, 2017) |
| " However, anti-proliferative effects of desipramine, a tricyclic antidepressant, in hepatocellular carcinoma are currently unknown." | 3.85 | Desipramine induces apoptosis in hepatocellular carcinoma cells. ( Kim, SJ; Yang, DK, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, DK | 1 |
| Kim, SJ | 1 |
1 other study available for desipramine and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Desipramine induces apoptosis in hepatocellular carcinoma cells.
Topics: Antidepressive Agents, Tricyclic; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Desipram | 2017 |